Menu
GeneBe

PAM

peptidylglycine alpha-amidating monooxygenase

Basic information

Region (hg38): 5:102753980-103029730

Links

ENSG00000145730NCBI:5066OMIM:170270HGNC:8596Uniprot:P19021AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PAM gene.

  • Inborn genetic diseases (24 variants)
  • not provided (15 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PAM gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
5
clinvar
3
clinvar
8
missense
24
clinvar
1
clinvar
4
clinvar
29
nonsense
0
start loss
0
frameshift
0
inframe indel
0
splice donor/acceptor (+/-2bp)
0
splice region
2
2
non coding
0
Total 0 0 24 6 7

Variants in PAM

This is a list of pathogenic ClinVar variants found in the PAM region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
5-102867275-T-A Benign (Aug 18, 2018)780546
5-102867328-G-C Benign (Dec 31, 2019)773172
5-102867355-G-A not specified Uncertain significance (Dec 28, 2023)3208261
5-102901384-G-A not specified Uncertain significance (Aug 09, 2021)3208264
5-102914002-T-C not specified Uncertain significance (Feb 28, 2023)2462061
5-102925031-G-A Likely benign (May 15, 2018)733728
5-102925040-A-G not specified Uncertain significance (Apr 13, 2023)2515985
5-102926580-T-C Benign (May 23, 2018)711434
5-102926666-G-C not specified Uncertain significance (Jul 27, 2021)2239571
5-102946885-C-T Benign (Jun 20, 2018)777977
5-102949575-C-A not specified Uncertain significance (Nov 21, 2022)2328715
5-102949581-C-A not specified Uncertain significance (Dec 15, 2023)3208269
5-102949583-T-A not specified Uncertain significance (Feb 28, 2023)2490491
5-102950766-T-G not specified Uncertain significance (Jun 10, 2022)2295246
5-102959909-A-G not specified Uncertain significance (Jan 31, 2023)2472112
5-102960019-C-T Benign (Jun 20, 2018)777978
5-102961171-A-G Likely benign (Jun 14, 2018)750247
5-102961218-T-G not specified Uncertain significance (Jul 25, 2023)2600389
5-102961219-G-T Likely benign (Jul 06, 2018)751791
5-102974125-A-G not specified Uncertain significance (Mar 14, 2023)2468808
5-102974349-T-G not specified Uncertain significance (Jun 01, 2023)2534441
5-102974426-A-C Benign (Jun 20, 2018)777979
5-102990287-A-C not specified Uncertain significance (Jul 09, 2021)2236279
5-102990304-G-C not specified Uncertain significance (Sep 17, 2021)2210490
5-103003091-A-G not specified Uncertain significance (Jun 27, 2023)2600316

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PAMprotein_codingprotein_codingENST00000304400 25277125
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.000006931.001256980501257480.000199
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.9604645260.8820.00002606387
Missense in Polyphen260301.720.861733776
Synonymous0.5671741840.9470.000009161858
Loss of Function4.381953.60.3550.00000273646

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001820.000181
Ashkenazi Jewish0.0005030.000496
East Asian0.0001640.000163
Finnish0.00009290.0000924
European (Non-Finnish)0.0002830.000281
Middle Eastern0.0001640.000163
South Asian0.00009810.0000980
Other0.0001660.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Bifunctional enzyme that catalyzes 2 sequential steps in C-terminal alpha-amidation of peptides. The monooxygenase part produces an unstable peptidyl(2-hydroxyglycine) intermediate that is dismutated to glyoxylate and the corresponding desglycine peptide amide by the lyase part. C-terminal amidation of peptides such as neuropeptides is essential for full biological activity.;

Recessive Scores

pRec
0.271

Intolerance Scores

loftool
0.191
rvis_EVS
-0.33
rvis_percentile_EVS
30.86

Haploinsufficiency Scores

pHI
0.588
hipred
Y
hipred_score
0.706
ghis
0.436

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.856

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Pam
Phenotype
adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; homeostasis/metabolism phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); respiratory system phenotype; embryo phenotype;

Zebrafish Information Network

Gene name
pam
Affected structure
brush border epithelial cell
Phenotype tag
abnormal
Phenotype quality
absent

Gene ontology

Biological process
peptide amidation;response to hypoxia;long-chain fatty acid metabolic process;regulation of transcription by RNA polymerase II;central nervous system development;heart development;lactation;response to pH;toxin metabolic process;protein amidation;ovulation cycle process;response to estradiol;regulation of actin cytoskeleton organization;odontogenesis;response to drug;response to copper ion;regulation of protein secretion;protein homooligomerization;response to glucocorticoid;oxidation-reduction process;maternal process involved in female pregnancy;limb development
Cellular component
extracellular region;trans-Golgi network;plasma membrane;cell surface;membrane;integral component of membrane;secretory granule membrane;neuron projection;perikaryon;perinuclear region of cytoplasm;extracellular exosome
Molecular function
peptidylglycine monooxygenase activity;peptidylamidoglycolate lyase activity;copper ion binding;calcium ion binding;protein binding;zinc ion binding;protein kinase binding;L-ascorbic acid binding